Filipa C.
- Country
- Portugal
- Department
- Serviço de Onco-Hematologia
Research Overview
- Dose-Escalation Study of [177Lu]Lu-DOTA-TATE with Standard Care in Newly Diagnosed Glioblastoma and as Monotherapy in Recurrent Glioblastoma.
- Phase Ib Dose-Escalation Study of [177Lu]Lu-NeoB with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and as Monotherapy in Recurrent Glioblastoma
- Phase 3 Randomized Study of Enfortumab Vedotin Versus Chemotherapy in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Data & Insights
Has run more than one trial at 45 of 184 partner sites.
Specializations
Oncology - Urological Cancers
This investigator specializes in the treatment of locally advanced and metastatic urothelial cancer, exploring innovative therapeutic approaches for patients who have undergone previous treatments.
- Advanced urothelial cancer management
- Novel therapeutic interventions
- Treatment-resistant cases
The research focus includes evaluating new therapeutic agents for improved patient outcomes in advanced urological malignancies.
Gastrointestinal Oncology
The investigator conducts research in advanced gastric and esophageal cancers, with particular emphasis on HER2-positive gastroesophageal adenocarcinoma (GEA).
- Targeted therapy combinations
- HER2-positive cancer treatment
- Advanced GEA management
Research activities focus on combination therapies incorporating targeted agents with conventional treatments.
Neuro-Oncology
The investigator specializes in treating glioblastoma, investigating both newly diagnosed and recurrent cases using innovative therapeutic approaches.
- Radiopharmaceutical therapy
- Combined modality treatment
- Recurrent glioblastoma management
The research encompasses novel radiopharmaceutical applications and combination strategies for glioblastoma treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.